Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10036MR)

This product GTTS-WQ10036MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10036MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4399MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-224818
GTTS-WQ2661MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ14637MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ4010MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ7284MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ4606MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ13943MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ2771MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW